Repligen Corporation

NasdaqGS:RGEN Rapport sur les actions

Capitalisation boursière : US$8.4b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Repligen Gestion

Gestion contrôle des critères 3/4

Le PDG Repligen's est Tony Hunt, nommé en May2015, a un mandat de 9.25 ans. La rémunération annuelle totale est $ 7.93M, composée du salaire de 11.1% et des bonus 88.9%, y compris les actions et options de la société. détient directement 0.23% des actions de la société, d'une valeur de $ 19.57M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.1 ans et 8.4 ans.

Informations clés

Tony Hunt

Directeur général

US$7.9m

Rémunération totale

Pourcentage du salaire du PDG11.1%
Durée du mandat du directeur général9.3yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de direction4.1yrs
Durée moyenne du mandat des membres du conseil d'administration8.4yrs

Mises à jour récentes de la gestion

Recent updates

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28
Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08
We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Feb 20
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Analyse de la rémunération des PDG

Comment la rémunération de Tony Hunt a-t-elle évolué par rapport aux bénéfices de Repligen?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

US$15m

Dec 31 2023US$8mUS$880k

US$42m

Sep 30 2023n/an/a

US$116m

Jun 30 2023n/an/a

US$138m

Mar 31 2023n/an/a

US$168m

Dec 31 2022US$8mUS$800k

US$186m

Sep 30 2022n/an/a

US$166m

Jun 30 2022n/an/a

US$159m

Mar 31 2022n/an/a

US$146m

Dec 31 2021US$8mUS$761k

US$128m

Sep 30 2021n/an/a

US$119m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$80m

Dec 31 2020US$5mUS$725k

US$60m

Sep 30 2020n/an/a

US$44m

Jun 30 2020n/an/a

US$31m

Mar 31 2020n/an/a

US$23m

Dec 31 2019US$4mUS$685k

US$21m

Sep 30 2019n/an/a

US$23m

Jun 30 2019n/an/a

US$27m

Mar 31 2019n/an/a

US$21m

Dec 31 2018US$14mUS$600k

US$17m

Sep 30 2018n/an/a

US$23m

Jun 30 2018n/an/a

US$23m

Mar 31 2018n/an/a

US$29m

Dec 31 2017US$3mUS$550k

US$28m

Rémunération vs marché: La rémunération totale de Tony ($USD 7.93M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 8.39M ).

Rémunération et revenus: La rémunération de Tony a augmenté alors que l'entreprise n'est pas rentable.


PDG

Tony Hunt (60 yo)

9.3yrs

Titularisation

US$7,929,275

Compensation

Mr. Anthony J. Hunt, also known as Tony, serves as Director at 908 Devices Inc. since March 2, 2022. He has been the Chief Executive Officer of Repligen Corporation since May 21, 2015 and served as its Pre...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Anthony Hunt
CEO & Director9.3yrsUS$7.93m0.23%
$ 19.1m
Olivier Loeillot
President & Chief Commercial Officerless than a yearUS$5.45mpas de données
Jason Garland
CFO & Chief Compliance Officerless than a yearUS$2.03mpas de données
James Bylund
Chief Operating Officer4.4yrsUS$3.74m0.0075%
$ 632.8k
Christine Gebski
Senior Vice President of Filtration & Chromatography4.1yrsUS$1.66m0.049%
$ 4.1m
Ralf Kuriyel
Senior Vice President of Research & Development7.8yrsUS$1.66m0.010%
$ 863.4k
Keith Robinson
Chief Information Officerno datapas de donnéespas de données
Sondra Newman
Global Head of Investor Relationsno datapas de donnéespas de données
Kimberly Cornwell
General Counsel & Global Head of Legalno datapas de donnéespas de données
Neil Whitfield
VP & Global Head of Sales1.8yrspas de donnéespas de données
Leslie Galvin
Vice President of Human Resources1.6yrspas de donnéespas de données
Kola Otitoju
Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics4.6yrspas de donnéespas de données

4.1yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de RGEN est considérée comme expérimentée (ancienneté moyenne 4.1 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Anthony Hunt
CEO & Director9.3yrsUS$7.93m0.23%
$ 19.1m
Glenn Muir
Independent Director8.8yrsUS$322.84k0.022%
$ 1.9m
Charles Leland Cooney
Member of Scientific Advisory Board8.4yrspas de donnéespas de données
Martin Madaus
Independent Director1.5yrsUS$453.50k0.0070%
$ 589.1k
Karen Dawes
Independent Chairperson of the Board18.9yrsUS$431.12k0.16%
$ 13.1m
Carrie Eglinton Manner
Independent Director4.2yrsUS$287.84k0.0050%
$ 419.9k
J. Love
Member of Scientific Advisory Board8.4yrspas de donnéespas de données
Konstantin Konstantinov
Member of Scientific Advisory Board & Independent Director8.4yrsUS$282.84k0.00095%
$ 79.9k
Steven Cramer
Member of Scientific Advisory Board8.4yrspas de donnéespas de données
Rohin Mhatre
Independent Director4.4yrsUS$287.84k0.0042%
$ 352.6k
Richard Braatz
Member of Scientific Advisory Boardno datapas de donnéespas de données
Nicholas Barthelemy
Independent Director10.2yrsUS$307.84k0.0071%
$ 595.8k

8.4yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de RGEN sont considérés comme expérimentés (ancienneté moyenne 8.4 ans).